ArticleJournal of molecular neuroscience : MN2011
Pituitary adenylate cyclase-activating polypeptide is protective against oxidative stress in human retinal pigment epithelial cells.
Article in Journal of molecular neuroscience : MN, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 29 citations in OpenAlex.
- Pituitary adenylate cyclase-activating polypeptide and mitochondrial homeostasis in neuronal injury: mechanisms and translational prospects.Frontiers in immunology · 2026Review
- Protective Effects of PACAP in Diabetic Complications: Retinopathy, Nephropathy and Neuropathy.International journal of molecular sciences · 2025Review
- Effects of Pituitary Adenylate Cyclase Activating Polypeptide on Cell Death.International journal of molecular sciences · 2022Review
- PACAP and NAP: Effect of Two Functionally Related Peptides in Diabetic Retinopathy.Journal of molecular neuroscience : MN · 2021Review
- Protective Effects of PACAP in Peripheral Organs.Frontiers in endocrinology · 2020Review
- PACAP Attenuates Optic Nerve Crush-Induced Retinal Ganglion Cell Apoptosis Via Activation of the CREB-Bcl-2 Pathway.Journal of molecular neuroscience : MN · 2019Article
- The synovial fluid neuropeptide PACAP may act as a protective factor during disease progression of primary knee osteoarthritis and is increased following hyaluronic acid injection.Innate immunity · 2019Article
- Pituitary Adenylate Cyclase Activating Polypeptide (PACAP) Reduces Oxidative and Mechanical Stress-Evoked Matrix Degradation in Chondrifying Cell Cultures.International journal of molecular sciences · 2019Article
- Signalling Alterations in Bones of Pituitary Adenylate Cyclase Activating Polypeptide (PACAP) Gene Deficient Mice.International journal of molecular sciences · 2018Article
- Age-related decline of autocrine pituitary adenylate cyclase-activating polypeptide impairs angiogenic capacity of rat cerebromicrovascular endothelial cells.The journals of gerontology. Series A, Biological sciences and medical sciences · 2015Article
- Microglia-Induced Maladaptive Plasticity Can Be Modulated by Neuropeptides In Vivo.Neural plasticity · 2015Review
- Effects of PACAP on intracellular signaling pathways in human retinal pigment epithelial cells exposed to oxidative stress.Journal of molecular neuroscience : MN · 2012Article
- Distribution and protective function of pituitary adenylate cyclase-activating polypeptide in the retina.Frontiers in endocrinology · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pituitary adenylate cyclase-activating polypeptide (PACAP) is a neuropeptide with potent neurotrophic and neuroprotective effects. We have previously shown that PACAP protects against several types of retinal injuries in vivo, including retinal ischemia, glutamate-induced excitotoxicity, UV A-induced lesion, and diabetic retinopathy. We have also shown that PACAP activates antiapoptotic pathways and inhibits proapoptotic signaling in retinal lesions in vivo. PACAP receptors have been identified on the retinal pigment epithelial cells and PACAP has been shown to inhibit interleukin secretion from pigment epithelial cells. It is not known, however, whether PACAP is protective in these cells. Human retinal pigment epithelial cells (ARPE-19 cell line) were exposed to in vitro oxidative stress by hydrogen peroxide. Cell survival was decreased in cells exposed to oxidative stress, which could be significantly and dose-dependently attenuated by 10 pM-1 μM PACAP treatment, as shown by MTT viability test. The protective effect of PACAP could be blocked by the receptor antagonist PACAP6-38. In addition, flow cytometry and JC-1 assay revealed that oxidative stress-induced apoptosis in retinal pigment epithelial cells could be decreased by PACAP treatment. In summary, these results show, for the first time, that PACAP is antiapoptotic in the retinal pigment epithelial cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.